We evaluated the association between self-monitoring of blood glucose (SMBG) use and sitagliptin or sitagliptin/ metformin (SSMT) adherence. SSMT was chosen as these medications have little risk of hypoglycemia and are believed to not require SMBG data for titration.
Methods:
This was an observational study using data extracted from a large United States insurance claims database (i3 InVision™ Data Mart, Ingenix, Inc.). Data were extracted on noninsulin-using patients initiating SSMT for each 12-month period pre- and post-SSMT initiation. Logistic regression was used to assess the relationship between SMBG use and the likelihood of being medication adherent (defined as a medication possession ratio of ≥75%) while controlling for covariates.
Results:
This analysis included 7,306 patients (57.6% male; mean age 54.2 years). Mean pre-SSMT hemoglobin A1c (HbA1c) was 8.0%. In the post-SSMT initiation period, 58% of patients were adherent with SSMT. Older age, male gender, prior use of oral diabetes medication, and lower HbA1c were associated with improved SSMT adherence. SMBG use was associated with improved adherence [odds ratio (OR) ranged from 1.198 to 1.338; p < .05] compared with patients with no SMBG use pre- or post-SSMT initiation. For patients who began SMBG after starting SSMT, greater SMBG use was associated with better adherence (OR 1.449 for higher vs 1.246 for lower strip use; p < .05).
Conclusions:
This study demonstrated that SMBG is associated with improved SSMT adherence. This relationship is strengthened with greater SMBG use.
OhkuboYKishikawaHArakiEMiyataTIsamiSMotoyoshiSKojimaYFuruyoshiNShichiriM. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract.1995;28 (2): 103–17.
2.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.;1998;352 (9131): 837–53.
3.
ADVANCE Collaborative GroupPatelAMacMahonSChalmersJNealBBillotLWoodwardMMarreMCooperMGlasziouPGrobbeeDHametPHarrapSHellerSLiuLManciaGMogensenCEPanCPoulterNRodgersAWilliamsBBompointSde GalanBEJoshiRTravertF. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.2008;358 (24): 2560–72.
4.
LawrenceDBRagucciKRLongLBParrisBSHelferLA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm.2006;12 (6): 466–71.
5.
SokolMCMcGuiganKAVerbruggeRREpsteinRS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care.2005;43 (6): 521–30.
6.
DuránAMartínPRunkleIPérezNAbadRFernándezMDel ValleLSanzMFCalle-PascualAL. Benefits of self-monitoring blood glucose in the management of new-onset type 2 diabetes mellitus: The St Carlos study, a prospective randomized clinic-based interventional study with parallel groups. J Diabetes.2010;2 (3): 203–11.
7.
KarterAJParkerMMMoffetHHSpenceMMChanJEttnerSLSelbyJV. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care.2006;29 (8): 1757–63.
8.
KolbHSchneiderBHeinemannLLodwigVScherbaumWAMartinS. Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3). J Diabetes Sci Technol.2007;1 (4): 487–95.
9.
MartinSSchneiderBHeinemannLLodwigVKurthHJKolbHScherbaumWA. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: An epidemiological cohort study. Diabetologia.2006;49 (2): 271–8.
10.
ZillichAJSutherlandJMKumberaPACarterBL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med.2005;20 (12): 1091–6.
11.
MillerSSt OngeEL. Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother.2006;40 (7- 8): 1336–43.
12.
Centers for Medicare and Medicaid Services [Internet]. Health Insurance Portability and Accountability Act of 1996. Public Law 104–191, 104th Congress. Available from: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed August 4, 2011.
13.
KarveSClevesMAHelmMHudsonTJWestDSMartinBC. Good and poor adherence: Optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin.2009;25 (9): 2303–10.
14.
CramerJARoyABurrellAFairchildCJFuldeoreMJOllendorfDAWongPK. Medication compliance and persistence: Terminology and definitions. Value Health.2008;11 (1): 44–7.
15.
BriesacherBAAndradeSEFouayziHChanKA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy.2008;28 (4): 437–43.
16.
SchneeweissSPatrickARMaclureMDormuthCRGlynnRJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: A population-based natural experiment. Circulation.2007;115 (16): 2128–35.
17.
SoumeraiSBPierre-JacquesMZangFRoss-DegnanDAdamsASGurwitzJAdlerGSafranDG. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: A national survey 1 year before the Medicare drug benefit. Arch Intern Med.2006;166 (17): 1829–35.
18.
ChapmanRHBennerJSPetrillaAATierceJCCollinsSRBattlemanDSSchwartzJS. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med.2005;165 (10): 1147–52.
19.
AhmedATKarterAJLiuJ. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours. Diabet Med.2006;23 (7): 795–802.
20.
GonzalezJSPeyrotMMcCarlLACollinsEMSerpaLMimiagaMJSafrenSA. Depression and diabetes treatment nonadherence: A meta-analysis. Diabetes Care.2008;31 (12): 2398–403.
21.
KressinNRWangFLongJBokhourBGOrnerMBRothendlerJClarkCReddySKozakWKroupaLPBerlowitzDR. Hypertensive patients' race, health beliefs, process of care, and medication adherence. J Gen Intern Med.2007;22 (6): 768–74.
22.
WinklerATeuscherAUMuellerBDiemP. Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly.2002;132 (27–28): 379–85.
23.
HoPMRumsfeldJSMasoudiFAMcClureDLPlomondonMESteinerJFMagidDJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med.2006;166 (17): 1836–41.
24.
FranciosiMLucisanoGPellegriniFCantarelloAConsoliACuccoLGhidelliRSartoreGSciangulaLNicolucciA; ROSES Study Group. ROSES: Role of self-monitoring of blood glucose and intensive education in patients with type 2 diabetes not receiving insulin. A pilot randomized clinical trial. Diabet Med.2011;28 (7): 789–96.
25.
PolonskyWHFisherLSchikmanCHHinnenDAParkinCGJelsovskyZPetersenBSchweitzerMWagnerRS. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: Results from the Structured Testing Program study. Diabetes Care.2011;34 (2): 262–7.
26.
FarmerAJWadeANFrenchDPSimonJYudkinPGrayACravenAGoyderLHolmanRRMantDKinmonthALNeilHA; DiGEM Trial Group. Blood glucose self-monitoring in type 2 diabetes: A randomised controlled trial. Health Technol Assess.2009;13 (15): 1–72.
27.
KleefstraNHortensiusJLogtenbergSJSlingerlandRJGroenierKHHouwelingSTGansROvan BallegooieEBiloHJ. Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). Neth J Med.2010;68 (1): 311–6.
28.
O'KaneMJBuntingBCopelandMCoatesVE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): Randomised controlled trial. BMJ.2008;336 (7654): 1174–7.
29.
KempfKKruseJMartinS. ROSSO-in-praxi: A self-monitoring of blood glucose-structured 12-week lifestyle intervention significantly improves glucometabolic control of patients with type 2 diabetes mellitus. Diabetes Technol Ther.2010;12 (7): 547–53.
30.
DicksonMPlauschinatCA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: Fixed dose vs free-combination treatment. Ethn Dis.2008;18 (2): 204–9.
31.
SvarstadBLShiremanTISweeneyJK. Using drug claims data to assess the relationship of medication adherence with hospitalization costs. Psychiatr Serv.2001;52 (6): 805–11.
32.
McCombsJSNicholMBStimmelGLSclarDABeasleyCMJrGrossLS. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry.1990;51 (Suppl): 60–9.
